期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肝脏常见小局灶性病变的Gd^+-EOB-DTPA磁共振增强表现与诊断 被引量：6

下载PDF
导出
摘要 目的:Gd+-EOB-DTPA是一种新型肝细胞特异性磁共振对比剂,注药后约50%与常规Gd+-DTPA一样经肾脏排泄,另外约50%被具有正常功能的肝细胞所摄取并排泄入胆道。当采用肝胆特异期扫描并结合反映肝局灶性病灶血供特点的动态增强T1WI扫描时,能够显著提高肝小(≤2.0cm)和微小(≤1.0cm)局灶性占位病灶的检出率及定性诊断符合率,本文就此作一简要介绍。
作者 丁莺 饶圣祥 陈财忠 曾蒙苏
机构地区 复旦大学附属中山医院放射科
出处 《放射学实践》 2013年第9期934-938,共5页 Radiologic Practice
基金 上海市科委医学引导类(124119a3100)
关键词 肝疾病 磁共振对比剂 磁共振成像
分类号 R575 [医药卫生—消化系统] R445.2 [医药卫生—影像医学与核医学]
  • 相关文献

参考文献23

  • 1Schuhmann Giampieri G, Schmitt-Willieh H, Press WR, et al. Pre- clinical evaluation of Gd-EOB DTPA as a contrast agent in MR imaging of the hepatobiliary system[J]. Radiology, 1992,183 ( 1 ) 59-64.
  • 2Weimn ann H J, Schuhmann-Giampieri G, Schmitt Willich H, et al. A new lipophilic gadolini umche]ate as a tissue specific contrast medium for MR imaging[J]. Magn Reson Med, 1991 ,22(2) : 233- 237.
  • 3Hamm B,Staks T,Muhler A,et al. Phase clinical evaluation of Gd EOB DTPA as a hepatobiliary MR contrast agent: safety, pharma cnkinetics,and MR imaging[J]. Radiology, 1995,195(3) :785-792.
  • 4Reimer P,Rummeny E J, Shamsi K, et al. Phase clinical evaluation of Gd EOB DTPA: dose, safety aspects, and pulse sequence[J]. Radiology, 1996,199(1) : 177-183.
  • 5Voga TJ,Kummel S, Hammerstingl R,et ah Liver tumors: con, parison of MR imaging with Gd EOB DTPA and Gd DTPA[J]. Radiology,1996,200(1):59- 67.
  • 6Raman SS,I.cary C,Bluemke DA,et al. hnproved characterization of focal liver lesions with liver specific gadoxetic acid disodium en hanced magnetic resonance imaging: a muhicenter phase 3 clinical trial[J]. J Comput Assist Tomogr,2010,34(2):163 -172.
  • 7Zech CJ, Herrmann KA,Reiser MF,et al. MR imaging in patients with suspected liver metastases: value of liver specific contrast a gent Gd EOB-DTPA[J]. Magn Reson Med Sci, 2007,6(1) :43- 52.
  • 8Halavaara J, Breuer J, Ayuso C, et al. I.iver tumor characteriza tion:comparison between liver specific Gadoxetic Acid Disodium enhanced MRI and biphasic CT-a muhicenter trial[J]. J Comput Assist Tomogr,2006,30(3) :345- 354.
  • 9Zech C J, C-razioli I., Breuer J, et al. Diagnostic performance and de scription of morphological features of focal nodular hyperplasia in Gd EOB DTPA-enhanced liver magnetic resonance imaging: re suhs of a multicenter triat[J]. Invest Radiol,2008,43(7): 504 -511.
  • 10Quillin SP, Atilla S, Brown JJ, et al. Characterization of focal hepatic masses by dynamic contrast enhanced MR imaging:findings in 311 lesions[J]. Magn Reson Imaging, 1997,15(3) :275-285.

同被引文献96

  • 1Meng-Su Zeng,Hui-Yi Ye,Liang Guo,Wei-Jun Peng,Jian-Ping Lu,Gao-Jun Teng,Josy Breuer,Yi Huan,Ping Li,Jian-Rong Xu,Chang-Hong Liang.Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients:a multicenter,open-label,phase Ⅲ study[J].Hepatobiliary & Pancreatic Diseases International,2013,12(6):607-616. 被引量：39
  • 2Seale M K, Catalano O A, Saini S, et al. Continuing medical ed- ucation: hepatobiliary-specific mr contrast agents: role in imaging the liver and biliary tree[J]. Radiographies, 2009,29(6) :1725- 1748.
  • 3Lee N K, Kim S, Lee J W, et al. Biliary MR imaging with Gd- EOBDTPA and its clinical applications[J]. Radiographics, 2009, 29(6):1707- 1724.
  • 4Weinmann H J, Schuhmann-Giampieri G,Schmitt-Willich H, et al. Anew lipophilic gadolini umchelate as a tissue specific contrast mediumfor MR imaging[J]. Magn Reson Med,1991,22(2) :233-237.
  • 5Do R K, Rusinek H, Taouli B, et al. Dynamic contrast-enhanced MR imaging of the liver: current status and future directions[J]. Magn Reson Imaging Clin N Am, 2009,17 (2):339 - 349.
  • 6Gsehwend S, Ebert W, Schultze-Mosgau M, et al. Pharmacoki- netics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment[J]. Invest Radiol,2011,46(9) :556-566.
  • 7Rose D M, Chapman W C, Brockenhrough A T, et al. Tran- scatheter arterial chemoemholization as primary treatment for hepatocellular carcinoma [ J ]. Am J Surg, 1999,177 ( 5 ) : 405 - 410.
  • 8Lencioni R, Llovet J M. Modified RECIST (mRECIST) assess- ment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010,30 (1) :52-60.
  • 9Bruix J, Sherman M. Practice guidelines committee, american association for the study of liver diseases, management of hepato- cellular carcinoma[J]. Hepatology, 2005,42 (5) : 1208- 1236.
  • 10Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization) : RECIST (response evaluation criteria in solid tumors) version 1. 1 and mRECIST (modified RECIST) : JIVROSG 0602[J]. Ups J Med Sci, 2013, 118(1):16-22.

引证文献6

二级引证文献102

放射学实践
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部